Clinical Efficacy of Amniotic Membrane Extract Eye Drops in Dry Eye Treatment
NCT05169931 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL
Last updated 2022-11-10
Summary
This prospective longitudinal study aims at evaluating the clinical efficacy of human amniotic fluid extract eye drops in the treatment of dry eye disease. 25 patients who are diagnosed with dry eye disease as defined by our criteria will be recruited from the cornea and dry eye clinic at Stein Eye Institute, UCLA. Pre-treatment baseline evaluations, 6 weeks, 12 weeks, and 24 weeks post treatment assessments will be performed by the principle investigator and co-investigator. All tests are considered non-invasive and are within the standard of practice in the evaluation for dry eye disease: (1) Ocular Surface Disease Index Questionnaire (OSDI); (2) Non-contact Tear Break-up Time (NITBUT); (3) Shirmer's test without anesthesia; (4) Ocular Surface Staining with Fluorescein and Lissamine green. Result of each test will be compared and analyzed to provide evidence of treatment efficacy. Treatment will be initiated for 12 weeks at a self-administered dose of one drop in both eyes two times per day. A follow-up of the study will be observed at the 24th week from the first day of treatment. All side effects and adverse events will be carefully observed and documented. Patients will be able to discontinue using the medication if they are not tolerating any side effects.
Conditions
- Dry Eyes Chronic
Interventions
- BIOLOGICAL
-
RegenerEyes
Biologic eye drop
Sponsors & Collaborators
-
University of California, Los Angeles
lead OTHER
Principal Investigators
-
Saba Al-Hashimi, M.D · University of California, Los Angeles
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-01-31
- Primary Completion
- 2022-04-30
- Completion
- 2022-05-31
More Related Trials
-
Tear Osmolarity Clinical Utility in Dry Eye Disease
NCT02417116 ·Status: COMPLETED ·Phase: NA
-
Predicting the Success of Dry Eye Disease Interventions Using Clinical Tests
NCT04125134 ·Status: TERMINATED ·Phase: PHASE4
-
Single Center, Prospective, Randomized, Controlled, Non-significant Risk
NCT03286166 ·Status: WITHDRAWN
-
Use of Autologous Serum Eye-drops as Tears in Patients With Recalcitrant Dry Eye
NCT01089985 ·Status: COMPLETED ·Phase: PHASE1
-
Role of Amniotic Membrane Extract Eye Drops as an Adjunctive Therapy in Resistant Corneal Ulcers
NCT06909149 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops
NCT05660681 ·Status: COMPLETED ·Phase: NA
-
Corneal Epithelial Stem Cells and Dry Eye Disease
NCT03302273 ·Status: COMPLETED ·Phase: NA
-
Study of the TearCare System in Dry Eye Disease
NCT03588624 ·Status: COMPLETED ·Phase: NA
-
The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes
NCT06898853 ·Status: RECRUITING ·Phase: NA
-
Tear Dynamics After Restasis Treatment in Dry Eye Patients
NCT00706940 ·Status: COMPLETED
-
Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops
NCT00001731 ·Status: COMPLETED ·Phase: PHASE2
-
Tear Osmolarity Changes After Instilling Isotonic Hyaluronate Artificial Tears
NCT01614847 ·Status: COMPLETED ·Phase: PHASE4
-
Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome
NCT05781451 ·Status: WITHDRAWN ·Phase: PHASE2
-
Comparison of Efficacy Between 100% Platelet-rich Plasma and 100% Serum Eye Drops in Dry Eye Disease
NCT04683796 ·Status: COMPLETED ·Phase: PHASE3
-
Management of Signs and Symptoms Associated With Dry Eye Disease
NCT04015219 ·Status: TERMINATED ·Phase: NA
-
A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease
NCT01733992 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease
NCT06544694 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease
NCT04030962 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Acceptability of Two Lubricant Eye Drops
NCT00756678 ·Status: COMPLETED ·Phase: PHASE4
-
DNase Treatment for Dry Eyes
NCT02193490 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye
NCT02420730 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of the Chronic Application of Tear Formulations
NCT01384851 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease
NCT05865379 ·Status: RECRUITING ·Phase: NA
-
A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult Participants
NCT05878067 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye
NCT01319773 ·Status: COMPLETED ·Phase: PHASE1